Mazdutide vs Hexarelin
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
- Hexarelin is a potent synthetic GHRP and the strongest GH secretagogue in its class per unit dose. It also exhibits unique cardioprotective properties through direct binding to cardiac CD36 receptors, independent of GH release. Its potency is balanced by a tendency to desensitize GH release with prolonged use, making cycling important.
- Half-Life
- ~7 days
- ~70 minutes
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 1.5 mg → 3 mg → 4.5 mg → 6 mg
- 100–200 mcg
- Frequency
- Once weekly
- 2–3 times daily
- Key Benefits
- Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
- Significant reduction in liver fat content (NAFLD/MASH potential)
- Improves HbA1c and fasting glucose in type 2 diabetes
- Favorable lipid profile changes (reduced triglycerides)
- Once-weekly subcutaneous dosing
- Potential for superior weight loss vs GLP-1 monotherapy
- Strongest GH pulse per mcg among GHRPs
- Unique direct cardioprotective effects via CD36
- Increased IGF-1 and muscle anabolism
- Accelerated recovery from training
- Bone density support
- Anti-aging via GH axis
- Potential cardiac rehabilitation benefits
- Side Effects
- Nausea
- Vomiting
- Decreased appetite
- Diarrhea
- +3 more
- Water retention
- Elevated cortisol
- Elevated prolactin (more pronounced than other GHRPs)
- Receptor desensitization with continuous use
- +1 more
- Stacks With
- —
- —